An alloy composition includes: 4.0-24.0 wt. % Cu; 0.5-3.0 wt. % Fe; 0.1 -0.5 wt. % Mn; 0.1 -0.3 wt. % Zr; 0-0.15 wt.% Si; 0-0.3 wt. % Mg; 0-0.3 wt. % Ti; balance Al, wherein the alloy with the average grain diameters ranging between 10 and 1000 μm produces minimum creep rates from 10-10to 3x10-9s-1at stresses up to 30 MPa, and from 10-10s-1to 2x10-8s-1 at stresses up to 70 MPa at 300 °C. A method of making an alloy is also disclosed.
C22F 1/04 - Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working of aluminium or alloys based thereon
C22C 21/08 - Alloys based on aluminium with magnesium as the next major constituent with silicon
2.
PHYSICS COMPUTING PROCESSOR SUPPORTING PHYSICS-INFORMED NEURAL NETWORKS AND FINITE ELEMENT METHODS FOR SCIENTIFIC COMPUTING
In an aspect, a physics computing unit (PhyCU) on an application-specific integrated circuit (ASIC) includes top general purpose SRAM banks in communication with a physics processing element (PHY-E) array. Bottom general purpose SRAM banks are in communication with the PHY-E array. Input SRAM banks are in communication with the PHY-E array, wherein the input SRAM banks are configured to store input data. A special parameters SRAM bank is in communication with the PHY-E array. An input mesh data compression module (IDCM) is in communication with the input SRAM banks and the PHY-E array, wherein the PHY-E is reconfigurable to operate in a physics-informed neural network (PINN) modes and a finite element method (FEM) mode. An offset-based sparsity address scheduler (OBSAS) is configured to compress the input data for sparse matrix-vector (SpMV) multiplication in the PINN modes and for conjugate gradient (CG) iterative method in the FEM mode.
Disclosed are systems and methods that include or utilize composable mammalian elements of transcription (COMET) including engineered recombinant proteins that regulate transcription and engineered DNA promoter sequences that are regulated by the engineered recombinant proteins. The elements may be composed to form logic gates, gene expression cascades and programs, and cell-based biosensors.
The disclosure is generally related to spherical nucleic acids (SNAs) comprising a protein corona, wherein the SNA comprises (i) a nanoparticle core and (ii) one or more oligonucleotides attached to the surface of the nanoparticle core, wherein the protein corona comprises a plurality of proteins. The disclosure also provides methods of using the same. The disclosure further provides methods of improving stability and/or extending blood circulation half-life of a spherical nucleic acid (SNA), the SNA comprising a nanoparticle core and one or more oligonucleotides attached to the surface of the nanoparticle core, the method comprising adsorbing a plurality of proteins on the surface of the SNA.
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
An oxygenation system producing oxygen for therapeutic cells housed in an implanted or external device, the oxygenation system comprising a first electrode comprising a first material layer stack and a catalyst film of a high surface area or catalyst particles on which at least one catalyst for electrocatalytic oxygen evolution reaction is disposed; and a second electrode comprising a second material stack.
C25B 11/081 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of a single catalytic element or catalytic compound the element being a noble metal
Disclosed herein are methods for preparing a copolymer from homopolymers. The method comprises compounding a bond-exchange catalyst and a polymer composition comprising a first homopolymer and a second homopolymer at an effective bond-exchange temperature for an effective bond-exchange time in a compounder, thereby preparing a compounded melt. Also disclosed is a method for preparing a compatibilized blend comprising compounding the copolymer prepared by a method described herein and a second polymer composition at a compatibilization temperature for a compatibilization time in a compounder.
The invention relates to cell-free systems, methods, and kits for bio-manufacturing natural or chemical products from readily available feedstocks, such as glucose. The systems, methods, and kits allow for cell-free bio-manufacturing of desired products in cell-free conditions, and the rapid optimization of conditions for preparing the products in cell-free conditions. Disclosed herein are systems, methods, and kits for the cell-free production of fatty acids, cannabinoids, and their intermediates.
A61K 51/10 - Antibodies or immunoglobulinsFragments thereof
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
9.
SYSTEMS AND METHODS FOR CELL-FREE ITERATIVE SITE SATURATION MUTAGENESIS AND ITS APPLICATION FOR THE DIRECTED EVOLUTION OF ENZYMES CATALYZING UNNATURAL REACTIONS
Disclosed are methods, compositions, systems, and protein compounds for the directed evolution of enzymes and proteins. The method comprising generating variant protein with a desired functionality, comprising one or more DNA expression templates comprising nucleic acid sequences encoding a variant protein, expressing the variant protein using cell-free protein synthesis; and analyzing one or more parameters associated with the variant protein.
A pelvic exam device includes an insert. The insert has a proximal end and a distal end, and the distal end of the insert has a dome shape. The pelvic exam device also includes a probe that mounts to the insert, where the probe includes a distal end that is positioned within the insert. The pelvic exam device also includes one or more cameras mounted to the distal end of the probe.
A61B 1/303 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor for the vagina, i.e. vaginoscopes
A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
A61B 1/018 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor characterised by internal passages or accessories therefor for receiving instruments
A61B 1/05 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor combined with photographic or television appliances characterised by the image sensor, e.g. camera, being in the distal end portion
A61B 1/06 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor with illuminating arrangements
11.
METHODS OF SYNTHESIZING DIALYKYLAMINO DISULFIDE DYNAMIC CROSSLINKERS
Provided are methods of synthesizing polymerizable alkylamino disulfide compounds which may be used as dynamic crosslinkers to form dynamic crosslinked polymer networks.
C07D 295/16 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
C07D 295/21 - Radicals derived from sulfur analogues of carbonic acid
C08K 5/43 - Compounds containing sulfur bound to nitrogen
In certain aspects, application-specific integrated circuit (ASIC) comprises a global ray-tracing scheduler (GRTS) in communication with a processing element (PE) array. The ASIC comprises a global memory access controller (GMAC) in communication with the PE array and the GRTS. The ASIC comprises a physical attributes MEM (PAMEM) in communication with the GRTS. The ASIC comprises a reconfigurable mixed-precision processing element of the PE array configured to support an inverse rendering mode for background extraction and a ray-tracing mode.
According to one aspect, kernel-based ergodic search using a robot may include receiving a target distribution indicative of a desired ergodic search coverage, generating a kernel-based ergodic metric based on the target distribution and a candidate trajectory, generating a kernel-based ergodic gradient based on the kernel-based ergodic metric, generating a trajectory based on the kernel-based ergodic gradient, and implementing the trajectory for the robot.
In one aspect, a system-on-a-chip (SoC) includes a plurality of programmable channels. The SoC includes an analog front end in communication with the plurality of programmable channels. The SoC includes a processing element array configured to receive output signals from the analog front end. The SoC includes an instruction memory supporting an instruction set architecture for supervising computing task of the processing element array, wherein the instruction memory comprises infinite impulse response instructions, discrete Fourier transform instructions, convolutional layer instructions, and fully connected layer instructions, wherein the processing element array is configured to execute instructions in the instruction memory, which, when executed, cause the processing element array to perform functions of a confusion matrix based teach-student convolutional neural network for low power and low latency, and perform functions of a sparsity controller for lower power.
G11C 11/54 - Digital stores characterised by the use of particular electric or magnetic storage elementsStorage elements therefor using elements simulating biological cells, e.g. neuron
G11C 7/10 - Input/output [I/O] data interface arrangements, e.g. I/O data control circuits, I/O data buffers
Certain aspects of the disclosure provide systems and methods for diagnosis and treatment of suicidal thought and behavior (STB) through reward-aversion judgment and contextual variables. Methods include generating a set of STB parameters associated with a subject, the set of STB parameters based on reward-aversion judgment variables and contextual variables and processing the set of STB parameters with a machine learning model to generate an STB prediction. The subject may then be treated based on the STB prediction.
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
16.
ALLOMELANIN-INSPIRED NANOADDITIVES FOR THE RADIATION PROTECTION OF POLYURETHANE
Aspects of the invention include a nanoadditive comprising a synthetic melanin-inspired nanoparticle, wherein: the synthetic melanin-inspired nanoparticle comprises a plurality of covalently-linked artificial melanin precursors, and each artificial melanin precursor independently comprises an artificial allomelanin precursor, an artificial eumelanin precursor, or a structural isomer thereof. Aspects of the invention include methods of generating polymer nanocomposites and methods of enhancing a mechanical property of a polymeric material.
Disclosed herein are mass spectrometry methods for determining glycoproteoform-based biomarkers. The methods comprise identifying, with a processor from mass spectrometry data of the glycoprotein, a set of glycoproteoforms where each of the glycoproteoforms have a measurable intact mass; generating, with the processor from the identified set of glycoproteoforms, a glycoproteoform network separated by saccharide features, determining, with the processor from the glycoproteoform network, a site-independent prediction of N-glycans mapped to biosynthesis pathways; and generating, with the processor from the determined N-glycans mapped to biosynthesis pathways, a glycan structure. The methods may be used to analyze a glycoprotein in a subject, analyze disease progression, or identify disease onset or a recovery.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
This invention discloses a monocrystalline superconductor and a method for fabricating the monocrystalline superconductor. The method includes providing an ink comprising a mixture of powders of RE2O3, BaCO3, and a Ba and/or Cu precursor with a binder and a solvent; extruding the ink into micro-lattices layer by layer to form a three dimension (3D)-printed object with a desired architecture; sintering the 3D-printed object to obtain a polycrystalline 3D-printed object comprising REBa2Cu3O7-x(RE123)+RE2BaCuO5 (RE211); and performing single-crystal growth of monocrystalline structures from the polycrystalline 3D-printed object to fabricate the monocrystalline superconductor, wherein RE represents a rare-earth element selected from the group consisting of Y, La, Sm, Nd, Gd, and Eu.
Provided are methods of synthesizing polymerizable alkylamino disulfide compounds which may be used as dynamic crosslinkers to form dynamic crosslinked polymer networks.
A three-dimensional printing system includes a tank, an arm, a rigid base, a light source, and a calibration tool. The tank contains a liquid photopolymer resin. The arm is configured to be movable relative to the tank. The rigid base is connected to the arm. The light source is configured to emit light to the tank to form an object on the rigid base. The calibration tool is connected to the tank. The calibration tool is configured to calibrate at least one of the tank and the arm.
B29C 64/393 - Data acquisition or data processing for additive manufacturing for controlling or regulating additive manufacturing processes
B29C 64/124 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material using layers of liquid which are selectively solidified
B29C 64/307 - Handling of material to be used in additive manufacturing
B33Y 30/00 - Apparatus for additive manufacturingDetails thereof or accessories therefor
B33Y 50/02 - Data acquisition or data processing for additive manufacturing for controlling or regulating additive manufacturing processes
A three-dimensional printing system includes a tank, a guide rail, an arm, a rigid base, and a light source. The tank contains a liquid photopolymer resin. The guide rail is mounted externally of the tank. The arm is movably connected to the guide rail. The arm is configured to be movable relative to the tank along the guide rail. The rigid base is connected to the arm. The light source is configured to emit light to the tank to form an object on the rigid base.
Provided is a process for hydrogenolysis of a polymer that includes providing in a reactor the polymer, hydrogen gas and a supported organometallic catalyst. The supported organometallic catalyst formed from an organometallic complex precatalyst and an acidic metal oxide support. The polymer is reacted with the supported organometallic catalyst in the presence of the hydrogen gas at a predetermined temperature in the reactor to produce a reduced polymer product having a weight average molecular weight less than the polymer.
C07C 4/22 - Preparation of hydrocarbons from hydrocarbons containing a larger number of carbon atoms by depolymerisation to the original monomer, e.g. dicyclopentadiene to cyclopentadiene
B01J 31/12 - Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides containing organo-metallic compounds or metal hydrides
B01J 31/26 - Catalysts comprising hydrides, coordination complexes or organic compounds containing in addition, inorganic metal compounds not provided for in groups
23.
DEVICES AND METHODS FOR TREATING A STRICTURE ALONG THE BILIARY AND/OR PANCREATIC TRACT
Medical devices and systems for treating a stricture, for example along the biliary and/or pancreatic tract, are disclosed. An example system may include a guidewire having a distal end and defining a lumen. A stiffening rod may be slidably disposed within the lumen. The stiffening rod may have a distal end and a distal end region disposed adjacent to the distal end. The stiffening rod may be configured to shift between a first position where the distal end of the stiffening rod is disposed proximally of the distal end of the guidewire and a second position where the distal end of the stiffening rod is disposed distally of the distal end of the guidewire.
A61B 17/22 - Implements for squeezing-off ulcers or the like on inner organs of the bodyImplements for scraping-out cavities of body organs, e.g. bonesSurgical instruments, devices or methods for invasive removal or destruction of calculus using mechanical vibrationsSurgical instruments, devices or methods for removing obstructions in blood vessels, not otherwise provided for
24.
TISSUE CULTURE PLATFORM HAVING MULTIPLE WELL CHAMBERS FLUIDICALLY COUPLED VIA MICROFLUIDIC CHANNELS AND SELECTOR VALVES
Tissue culture platforms that may be configured for tissue culture or biological cell culture, and methods for use thereof, are described. In general, the tissue culture platforms include multiple well chambers that are fluidically coupled by one or more channels. Flow between the different well chambers is controlled via one or more selector valves, enabling a single tissue culture platform that can provide multiple integrated culture subsystems, multiple non-interacting culture subsystems, or combinations thereof.
Systems and methods for detecting one or more analytes in a liquid sample are disclosed herein using a microcantilever coated with polynucleotides that comprise operator sequences specific to allosteric transcription factors are provided herein. Presence of analytes in the sample release the allosteric transcription factors causing a detectable change in the configuration of the microcantilever.
The present disclosure describes use and construction of low-inertia thin film clutches and transmissions. The low-inertia thin film clutches include a soft inter-layer between the switchable adhesion layer and a backing to achieve a uniform force distribution. This design allows clutches to engage and disengage instantly with fixed or moving surfaces and prevents slipping and/or creeping. The adhesion layer uses a switching mechanism to switch between on and off states. The soft inter-layer, which is laminated between the switchable adhesion layer and an inextensible yet flexible backing, ensures uniform force distribution.
H02N 13/00 - Clutches or holding devices using electrostatic attraction, e.g. using Johnson-Rahbek effect
F16D 27/10 - Magnetically-actuated clutchesControl or electric circuits therefor with an electromagnet not rotating with a clutching member, i.e. without collecting rings
27.
METHODS FOR PERFORMING HIGH-SPEED, SCANNED LASER STRUCTURING OF MULTI-LAYERED ECO-BIORESORBABLE MATERIALS AND FABRICATING BIORESORBABLE ELECTRONIC DEVICES, AND APPLICATIONS THEREOF
This invention relates to methods for performing laser structuring of multi-layered ecoresorbable or bioresorbable materials and fabricating a bioresorbable electronic device using pisosecond-pulsed laser, devices fabricated by the methods, and applications of the same. Specifically, the method includes: sequentially forming a plurality of ecoresorbable or bioresorbable material layers on a flexible substrate; patterning, locally thinning or ablating, using a picosecond-pulsed laser system, the ecoresorbable or bioresorbable material layers to form sensing components and interconnection traces of the bioresorbable electronic device; and patterning and ablating, using a picosecond-pulsed laser system, the flexible substrate to form stretchable portions of the bioresorbable electronic device. The material layers may be formed on the flexible substrate by physical lamination, transfer printing, deposition or growth techniques. The use of the picosecond-pulsed laser is advantageous because the ablation process occurs on timescales sufficiently short to limit thermal diffusion and the associated spread of the heat-affected zone.
Disclosed are compositions and methods related to RNA interference (RNAi) and the use of RNAi active sequence for treating diseases and disorders. Particular disclosed are toxic RNAi active sequences such as siRNA and shRNA for killing cancer cells. The disclosed toxic RNAi active sequences typically include trinucleotide repeats and preferentially target the expression of multiple essential genes for cell survival and/or growth.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
Provided herein are peptide amphiphiles comprising a β-sheet forming peptide sequence conjugated to two or more vinylidene fluoride (VDF) monomers, and nanoscale ferroelectric structures comprising the same.
C07K 17/02 - Peptides being immobilised on, or in, an organic carrier
B82Y 25/00 - Nanomagnetism, e.g. magnetoimpedance, anisotropic magnetoresistance, giant magnetoresistance or tunneling magnetoresistance
C07K 5/103 - Tetrapeptides the side chain of the first amino acid being acyclic, e.g. Gly, Ala
C07K 5/113 - Tetrapeptides the side chain of the first amino acid containing more carboxyl groups than amino groups, or derivatives thereof, e.g. Asp, Glu, Asn
30.
IRON-TUNGSTEN REDOX SYSTEM AND APPLICATIONS OF SAME
xxx represents a concentration (at%) of tungsten (W) in the powder architecture and is in a range of about 1-75 at%, wherein the powder architecture comprises powder bed, powder suspension, foams, fibers, and/or printed microlattices.
B22F 9/22 - Making metallic powder or suspensions thereofApparatus or devices specially adapted therefor using chemical processes with reduction of metal compounds starting from solid metal compounds using gaseous reductors
C22C 33/02 - Making ferrous alloys by powder metallurgy
C22C 38/12 - Ferrous alloys, e.g. steel alloys containing tungsten, tantalum, molybdenum, vanadium or niobium
B33Y 70/10 - Composites of different types of material, e.g. mixtures of ceramics and polymers or mixtures of metals and biomaterials
31.
THREE-DIMENSIONAL CONSTRUCTION BLOCKS WITH CONFIGURATION-INVARIANT ATTACHMENT
A construction block system includes a shell, where the shell forms a cell of the system. The system also includes one or more magnets embedded in each of the exterior sides of the shell, where the one or more magnets are mounted such that magnets along opposing faces of aligned cells have opposite poles.
A method of performing automatic ion control for mass spectrometry includes acquiring, by charge detection mass spectrometry, a mass spectrum comprising a plurality of peaks representing intensity as a function of mass-to-charge ratio (m/z) of a population of ions analyzed by a mass analyzer during an acquisition event. Based on the mass spectrum, a measured signal density of a selected m/z range of the mass spectrum is determined. An ion population control parameter for a subsequent acquisition event is set based on the measured signal density and a target signal density. The ion population control parameter regulates a population of ions analyzed by the mass analyzer during the subsequent acquisition event.
Provided are random copolymers exhibiting the ability to self-heal, including under ambient conditions (room temperature and atmospheric pressure). Compositions comprising the random copolymers are also provided. The self-healing, random copolymer is a polymerization product of monomers comprising a branched alkyl (meth)acrylate and a comonomer, wherein the branched alkyl (meth)acrylate is present at an amount of at least 40 mol %.
C08F 220/18 - Esters of monohydric alcohols or phenols of phenols or of alcohols containing two or more carbon atoms with acrylic or methacrylic acids
C09D 125/14 - Copolymers of styrene with unsaturated esters
C09D 133/06 - Homopolymers or copolymers of esters of esters containing only carbon, hydrogen and oxygen, the oxygen atom being present only as part of the carboxyl radical
37.
MILLIMETER-SCALE WIRELESS IMPLANTABLE AUTONOMOUS OXYGENATOR PLATFORM AND APPLICATIONS THEREOF
An oxygenation system producing oxygen for therapeutic cells housed in an implanted or external system housing the therapeutic cells. The oxygenation system comprises a mm-scale oxygenator having at least one metal electrode; a miniaturized application-specific integrated circuit (ASIC) controlling an oxygen production by the oxygenator; a miniaturized communication unit; and a miniaturized power unit.
C25B 1/04 - Hydrogen or oxygen by electrolysis of water
C25B 11/077 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of a single catalytic element or catalytic compound the compound being a non-noble metal oxide
In an aspect, the invention provides therapeutic agents comprising brush polymers that address challenges associated with conventional administration of free therapeutic peptides. In an embodiment, for example, the invention provides brush polymers incorporating one or more therapeutic peptides comprising a sequence having 75% or greater sequence identity with an 8 to 12 amino acid fragment of SEQ ID NO: 218 (MDLIDILWRQDIDLGVSREVFDFS). Therapeutic agents of the invention comprising brush polymers include high-density brush polymers including cross-linked brush polymers, brush block copolymers, and brush random copolymers. In an embodiment, brush polymers of the invention exhibit proteolysis-resistant characteristics and maintain their biological function during formulation and administration. The invention also includes methods of making and using therapeutic agents comprising brush polymers.
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
G01N 33/537 - ImmunoassayBiospecific binding assayMaterials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
40.
ORTHOGONAL TRANSLATION SYSTEMS AND METHODS FOR IDENTIFYING COMPONENTS THEREOF
Provided herein are compositions comprising dual-porosity membranes an microporous outer layer and a nanoporous inner layer, and methods of use thereof. In particular, polycarbonate-based polyurethane bilayer membranes are formed in the presence of pore-forming agents that allow for differ pore sizes to be achieved in inner and outer layers. The dual-porosity membranes herein find use in encapsulating therapeutic cells for transplantation.
A beam for supporting a plurality of prismatic batteries in battery enclosure of an electric vehicle includes a base, having a lower elongate horizontal flange, and an upper elongate horizontal flange, narrower than the lower elongate horizontal flange, spaced above the lower elongate horizontal flange by a vertical web. A web member can be disposed on the upper elongate horizontal flange of the base, and includes first and second elongate exterior vertical wall members. At least two elongate inserts disposed between the vertical exterior wall members, and configured to at least in part form at least one longitudinally extending channel between them. The elongate inserts can be made of metal and the longitudinally extending channel provides a pathway for cooling fluid. A cap can engage the upper edges of the vertical wall members and enclose the metal inserts in the space between the first and second vertical wall members.
H01M 50/249 - MountingsSecondary casings or framesRacks, modules or packsSuspension devicesShock absorbersTransport or carrying devicesHolders specially adapted for aircraft or vehicles, e.g. cars or trains
H01M 10/647 - Prismatic or flat cells, e.g. pouch cells
H01M 10/653 - Means for temperature control structurally associated with the cells characterised by electrically insulating or thermally conductive materials
H01M 10/6568 - Liquids characterised by flow circuits, e.g. loops, located externally to the cells or cell casings
H01M 50/209 - Racks, modules or packs for multiple batteries or multiple cells characterised by their shape adapted for prismatic or rectangular cells
H01M 50/231 - MountingsSecondary casings or framesRacks, modules or packsSuspension devicesShock absorbersTransport or carrying devicesHolders characterised by the material of the casings or racks having a layered structure
44.
METHOD OF ELECTRODEPOSITION IN SEAWATER FOR THE GROWTH OF CONSTRUCTION MATERIALS
The present invention relates to a method to produce calcium rich-based aggregates by electrodeposition in salty aqueous CO2 enriched solutions, that can be used in the construction industry. The method includes filtering an aqueous salty solution to produce an aqueous salty solution free of organic debris or pollutants, adjusting a temperature and pH in a conditioning reactor CR1 to produce an aqueous salty solution, bringing the aqueous salty solution from CR1 to a continuous reactor CR2 equipped with an electroactive substrate comprising at least one cathode and at least one anode connected to an electrical DC supply, injecting in CR2 a flux of a gas mixture containing CO2 (C-gas) in contact with the flux of the aqueous solution, applying to the flux of the CO2-enriched aqueous solution a constant DC current, and recovering the calcium rich-based aggregates deposited on the electroactive substrate and/or on the bottom of CR2.
Disclosed are compositions, systems, kits, and methods for detecting an analyte in a sample by regulated in vitro transcription. The compositions, systems, kits, and methods typically comprise and/or utilize one or more components selected from: (a) an RNA polymerase; (b) an allosteric transcription factor (ATF), wherein the ATF binds an analyte or target molecule as a ligand; (c) a reporter molecule, and (d) an engineered transcription template; and/or any combination thereof. The engineered transcription template typically comprises a promoter sequence for the RNA polymerase and an operator sequence for the ATF. The promoter sequence and operator sequence are operably linked to a sequence encoding an RNA, wherein the ATF modulates transcription of the encoded RNA when the ATF binds the analyte or target molecule as a ligand, wherein the transcribed RNA generates or interferes with a detectable signal in conjunction with the reporter molecule.
THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (USA)
Inventor
Rogers, John A.
Fang, Hui
Zhao, Jianing
Song, Enming
Lee, Yoon Kyeung
Abstract
Provided are methods of making a liquid and liquid vapor-proof material, and relates long-term implantable electronic devices. The method comprises providing a first substrate having a first-side encapsulating layer supported by at least a portion of the first substrate; providing a material onto the first-side encapsulating layer; providing a second substrate having a second-side encapsulating layer supported by at least a portion of the second substrate; covering an exposed surface of the material provided onto the first-side encapsulation layer with the second-side encapsulating layer; wherein said encapsulating layers are substantially defect free so that liquid or liquid vapor is prevented from passing through each of the encapsulating layers; thereby making the liquid or liquid vapor-proof material.
A microbial fuel cell includes a first conductive electrode that hosts a plurality of microbes that break down organic matter to perform oxidation and release electrons. The first conductive electrode is an anode. The microbial fuel cell also includes a second conductive electrode operatively coupled to the first conductive electrode. The second conductive electrode is a cathode that is vertically oriented in soil that includes the organic matter. Additionally, at least a portion of the cathode is contact with air.
C25B 9/19 - Cells comprising dimensionally-stable non-movable electrodesAssemblies of constructional parts thereof with diaphragms
C25B 9/65 - Means for supplying currentElectrode connectionsElectric inter-cell connections
C25B 9/23 - Cells comprising dimensionally-stable non-movable electrodesAssemblies of constructional parts thereof with diaphragms comprising ion-exchange membranes in or on which electrode material is embedded
C25B 9/17 - Cells comprising dimensionally-stable non-movable electrodesAssemblies of constructional parts thereof
Method for treating a subject for a cancer are provided. The method may include treating a subject for a cancer responsive to MYC inhibition, the method comprising administering a MYC inhibitor to the subject if the MYC inhibitor Response Signature (MiRS) score for the cancer is greater than 0.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
C07D 231/12 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
50.
VIROFIND: A NOVEL PLATFORM FOR DETECTION AND DISCOVERY OF THE ENTIRE VIROGENOME IN CLINICAL SAMPLES
The invention relates to methods, systems and components thereof for detecting and discovering viruses in a clinical sample. In particular, the invention relates to methods, systems, and components thereof for detecting and discovering a plurality of viruses in a clinical sample.
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
51.
CELL TYPE SELECTIVE DELIVERY OF EXOSOME CARGO USING NOTCH LIGAND-RECEPTOR SYSTEM
Provided herein are engineered exosomes and uses thereof for cell-type selective delivery of cargo. In particular, provided herein are engineered exosomes expressing a Notch ligand binding domain and uses thereof for targeted delivery of therapeutic cargo to cells expressing Notch ligand, such as neurons.
A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
The present disclosure generally provides compositions and methods for increasing the activity of an annexin protein to treat a cellular membrane injury in a patient in need thereof. In some aspects, the disclosure provides methods of treating a patient suffering from a nerve injury comprising administering a therapeutically effective amount of a composition comprising an agent that increases the activity of an annexin protein. In further aspects, the disclosure provides methods of reducing serum or plasma level of lactate dehydrogenase (LDH), cardiac troponin T, cardiac troponin I, creatine kinase (CK), or a combination thereof, in a patient in need thereof, comprising administering a therapeutically effective amount of an agent that increases the activity of an annexin protein to the patient.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
53.
ANALYZING OLIGOMERIC PROTEIN STRUCTURES BY MASS SPECTROMETRY
Disclosed herein are methods for analyzing oligomeric protein structures by mass spectrometry. The method includes providing a sample having one or more oligomers; producing, with an ion source, ions of the sample, each of the ions having a mass-to-charge (m z) ratio; detecting a multiplicity of ions generated with a current detector; determining ion masses for each of the multiplicity of ions detected with the current detector with a mass analyzer; generating a mass-domain spectrum from the ion masses with the mass-analyzer, the mass-domain spectrum having one or more mass-domain peaks; and determining one or more metrics capturing the mass heterogeneity and/or mass abundance of oligomers. Methods for diagnosing a subject, assessing treatment efficacy, and assessing treatment efficacy are also provided.
G01N 27/62 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating the ionisation of gases, e.g. aerosolsInvestigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electric discharges, e.g. emission of cathode
H01J 49/26 - Mass spectrometers or separator tubes
H01J 49/42 - Stability-of-path spectrometers, e.g. monopole, quadrupole, multipole, farvitrons
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
G01N 33/52 - Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper
Disclosed herein are systems for electron catalyzed molecular recognition and methods of making and using the same. The system comprises an electron source for providing an electron, a redox-active substrate capable of accepting the electron from the electron source, and a catalytic intermediate formed noncovalently from the substrate and a second molecule, wherein the energy barrier for forming the catalytic intermediate is decreased by the redox-active substrate accepting the electron from the electron source.
Provided herein are inhibitors of the TFPJ2-CD51-STAT6 signaling axis and methods for the treatment of cancer (e.g., glioblastoma) therewith. In particular, inhibitors of expression or activity of components of the TFPJ2-CD51-STAT6 signaling axis are provided, with or without an immune checkpoint inhibitor, for the treatment of glioblastoma.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
56.
METHODS AND SYSTEMS FOR ELECTROLYZING HYDROCARBONS COUPLED WITH CO2 CAPTURE
Methods and systems for the electrosynthesis of an oxidized product (e.g., ethylene glycol) from a hydrocarbon (e.g., ethylene) are provided. Electrosynthesis of the oxidized product is coupled with CO2 capture in a catholyte, which may be subsequently released. An illustrative method comprises (a) delivering a cathode feed comprising CO2 to a cathode in contact with a catholyte; (b) delivering an anode feed comprising a hydrocarbon to an anode in contact with an anolyte; and (c) generating hydroxide in the catholyte to dissolve CO2 therein, while oxidizing the hydrocarbon in the anolyte, by generating a potential difference between the cathode and the anode.
C25B 9/23 - Cells comprising dimensionally-stable non-movable electrodesAssemblies of constructional parts thereof with diaphragms comprising ion-exchange membranes in or on which electrode material is embedded
C25B 11/081 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of a single catalytic element or catalytic compound the element being a noble metal
57.
MULTI-ARMED DENDRIMERIC OLIGONUCLEOTIDE NANOARCHITECTURES TO TARGET THE CYCLIC GMP-AMP (CGAS)/CYCLIC GMP-AMP RECEPTOR STIMULATOR OF INTERFERON GENES (STING) PATHWAY
A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
A61K 47/59 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
58.
UNIVERSAL METHOD FOR SYNTHESIS OF METALLIC NANOPARTICLES VIA SCANNING PROBE LITHOGRAPHY
A method for forming metal or metal oxide nanoparticles on a substrate can include depositing a precursor ink on a hydrophobic surface of a substrate to form nanoreactors on the hydrophobic surface. The precursor ink includes a metal precursor and a non-coordinating polymer dissolved in a solvent. The process can then include evaporating the solvent from the nanoreactors, wherein upon evaporation of the solvent, the polymer and the metal precursor phase separate and the metal precursor aggregates on a surface of the nanoreactors. After the solvent is evaporated, the polymer is removed to thereby leave the aggregated metal precursor in contact with the hydrophobic surface. The resulting aggregated metal precursor is then annealed to form the metal or metal oxide nanoparticle.
B22F 9/22 - Making metallic powder or suspensions thereofApparatus or devices specially adapted therefor using chemical processes with reduction of metal compounds starting from solid metal compounds using gaseous reductors
B82Y 40/00 - Manufacture or treatment of nanostructures
59.
COMPOSITIONS AND METHODS FOR THE TREATMENT OF GLIOBLASTOMA WITH A DUAL TARGETING ANTI-TUMOR COMPOSITION
The present disclosure provides compositions and methods for the treatment of cancer (e.g., glioblastoma). In particular, the present disclosure provides a dual targeting anti-tumor composition comprising a LOX inhibitor and a CLOCK-OLFML3 inhibitor, and methods of use thereof for treating glioblastoma in combination with or without an anti-programmed death-1 (PD1) therapy or radiotherapy.
A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
Methods and compositions for treating and/or preventing hernias in subjects in need thereof. The methods of treatment can include administering to the subject one or more therapeutic agents that modulate the activity of progesterone and/or the progesterone receptor in the subject.
A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
A61K 31/567 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
A61K 31/57 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
Disclosed are polynucleotides, compositions, and methods related to RNA interference (RNAi). In particular, disclosed are toxic RNAi sequences comprising a dsRNA having a first strand, otherwise referred to as an “A” strand, and a second strand, otherwise referred to as a “B” strand and dinucleotide repeats. Also included are methods of using said complexes for killing cancer cells and treating cancer.
A transient closed-loop system for cardiac pacing and/or defibrillator therapy for a subject includes a bioresorbable module configured to at least partially attach to an epicardial interface of the subject's heart for the cardiac pacing; at least one skin-interfaced module configured to attach to an outer surface of the subject's skin, wherein the bioresorbable module is in wireless communication with the at least one skin-interfaced module; and a control module in wireless communication with the at least one skin-interfaced module.
G16H 40/40 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the management of medical equipment or devices, e.g. scheduling maintenance or upgrades
63.
METAL-ORGANIC FRAMEWORK MATERIALS FOR CARBON DIOXIDE CAPTURE UNDER HIGH HUMIDITY
A material is provided comprising a Zn-(methyltriazolate)-(oxalate) metal-organic framework (MOF) having a chemical formula of Zn(3-methyl-1H-1,2,4-triazolate)(oxalate)0.5 (Zn(mtz)(ox)0.5) and comprising oxalate groups forming oxalate layers and (mtz)Zn2(mtz) groups forming (mtz)Zn2(mtz) layers. In some embodiments, oxalate groups of adjacent oxalate layers are parallel, wherein each methyl group of each (mtz)Zn2(mtz) group is oriented in opposing directions, and wherein adjacent methyl groups of adjacent (mtz)Zn2(mtz) groups and on a same side of planes defined by the oxalate groups are oriented in opposing directions. In other embodiments, oxalate groups of adjacent oxalate layers are non-parallel, and wherein each methyl group of each (mtz)Zn2(mtz) group is oriented in the same direction. Methods of using the materials to capture CO2 are also provided. Methods for synthesizing Zn-(methyltriazolate)-(oxalate) MOFs are also provided.
B01J 20/22 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising organic material
B01D 53/04 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by adsorption, e.g. preparative gas chromatography with stationary adsorbents
B01J 20/30 - Processes for preparing, regenerating or reactivating
Provided are circuits for integrating image processing into image sensors. Multiple configurations of sensors are described that generate specific motion and shape-based responses to changes in received light intensity. These sensor configurations may be used to pre-process images and to provide additional context to light intensity data. The sensor configurations may include memory circuits and signal conditioning.
This invention relates to a virtual reality (VR) system, comprising a pair of concave lenses; and a pair of screens, arranged in relation to the pair of concave lenses and eyes of a subject, for fully illuminating the visual field of view (FOV) of the subject, and configured to illuminate each eye with an about I80-degree field of view in all directions.
B01J 20/22 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising organic material
B01D 53/14 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by absorption
67.
MOIRÉ SYNAPTIC TRANSISTORS AND APPLICATIONS OF SAME
The invention relates to moiré synaptic transistors and crossbar array comprising M columns and N rows of moiré synaptic transistors. The moiré synaptic transistor comprises a top gate, a bottom gate, and an asymmetric moiré heterostructure disposed between the top gate and the bottom gate; and a source and a drain spatial-apart formed on the asymmetric moiré heterostructure to define a conductance channel in the asymmetric moiré heterostructure therebetween, and wherein the top gate and the bottom gate are capacitively coupled with the conductance channel.
Systems and methods that enable automated spray deposition of biological specimens carried on microscope slides are described herein. Aspects of the technology are directed, for example, to automated specimen deposition systems and methods of generating high-quality, reproducible specimen-bearing microscope slides in automated processing systems.
A cathode material has the chemical formula Li4+δMx1M′y1M″z1O8 or Li2+δMx2M′y2M″z2O4 where 0≤δ≤1, x1, y1, z1 are integers (+/−0.5) and x1+y1+z1=4, and x2, y2, z2 are integers (+/−0.05) and x2+y2+z2=2. A method for discovering a cathode material includes estimating synthesizability for a plurality of cathode material compositions, selecting a first subset of cathode material compositions from the plurality of cathode material compositions as a function of the estimated synthesizability and metal-ion diffusion availability, estimating voltage discharge, charge capacity, and oxygen stability for the first subset of cathode material compositions, and selecting a second subset of cathode material compositions from the first subset plurality of cathode material compositions as a function of the estimated voltage discharge, charge capacity, and oxygen stability.
H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
A cathode for a battery includes a cathode material with the chemical formula Li1+δFexCryO2 where 0≤δ≤1, and δ+x+y=2. In some variations, the cathode material has a disordered rock-salt crystal structure and the chemical formula Li1+δFexCryO2 where 0≤δ≤1, and δ+x+y=2. And in at least one variations, a method of forming the cathode material includes wet ball milling solid precursors of lithium, iron, and chromium and forming a slurry, drying the slurry and forming a powder, sintering the powder, and dry ball milling the powder and forming the cathode material with the disordered rock-salt crystal structure and the chemical formula Li1+δFexCryO2 where 0≤δ≤1, and δ+x+y=2.
A 3D printing system includes a tank containing a liquid photopolymer resin. A textured substrate is connected to the tank. The textured substrate is configured such that light passes therethrough into the liquid polymer resin. A layer of an inert material is disposed on the textured surface. The liquid photopolymer resin and the inert material are discharged from the tank through a tank outlet. Additional liquid photopolymer resin and additional inert material are added to the tank through a tank inlet.
B29C 64/124 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material using layers of liquid which are selectively solidified
The present disclosure provides methods and systems to artificial intelligence for early recognition of rare skin diseases. In particular, the present disclosure provides methods and systems for early recognition of squamous cell carcinoma in epidermolysis bullosa and methods and systems for treating and/or preventing SCCs.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
G06V 10/764 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using classification, e.g. of video objects
G06V 10/774 - Generating sets of training patternsBootstrap methods, e.g. bagging or boosting
G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
Automated cell staining systems and methods are disclosed herein. In particular, the staining systems disclosed herein provide low-volume, automated bench top staining systems for staining biological samples contained on a cytological slide.
B05C 3/02 - Apparatus in which the work is brought into contact with a bulk quantity of liquid or other fluent material the work being immersed in the liquid or other fluent material
B05C 3/08 - Apparatus in which the work is brought into contact with a bulk quantity of liquid or other fluent material the work being immersed in the liquid or other fluent material with special provision for agitating the work or the liquid or other fluent material the work and the liquid or other fluent material being agitated together in a container, e.g. tumbled
Disclosed are amino, halo-substituted cyclopentene, cyclopentane, or 4-methylenecyclopent-1-ene carboxylic acid compounds. The disclosed compounds and compositions thereof may be utilized in methods for modulating human ornithine δ-amino-transferase (hOAT) activity, including methods for treating diseases or disorders associated with hOAT activity or expression such as cell proliferative diseases and disorders.
C07C 229/48 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms of the same non-condensed ring
A61K 31/196 - Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
75.
METHOD OF FORMING METAL ION DOPED HALIDE PEROVSKITE MEGALIBRARIE
A method of forming metal ion doped halide perovskite nanocrystals includes forming metal halide perovskite nanocrystals, exposing the nanocrystals to a solvent vapor assisted recrystallization, and diffusing a metal ion dopant into the nanocrystals in a thermal annealing assisted cation exchange process.
H10K 50/135 - OLEDs or polymer light-emitting diodes [PLED] characterised by the electroluminescent [EL] layers comprising mobile ions
H10K 71/13 - Deposition of organic active material using liquid deposition, e.g. spin coating using printing techniques, e.g. ink-jet printing or screen printing
H10K 71/40 - Thermal treatment, e.g. annealing in the presence of a solvent vapour
76.
Potent and Selective Human Neuronal Nitric Oxide Synthase Inhibitors
Disclosed are 2-aminopyridine derivative compounds for use as inhibitors of nitric oxide synthase (NOS). In particular, the field of the invention relates to 2-aminopyridine derivative compounds for use as inhibitors of neuronal nitric oxide synthase (nNOS), which are formulated as pharmaceutical compositions for treating diseases and disorders associated with nNOS such as Alzheimer's, Parkinson's, and Huntington's diseases, and amyotrophic lateral sclerosis, cerebral palsy, stroke/ischemic brain damage, and migraine headaches.
C07D 213/73 - Unsubstituted amino or imino radicals
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 401/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 413/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
77.
POLYURETHANE WASTE BLENDING USING DYNAMIC URETHANE EXCHANGE
Polyurethane waste blending using dynamic urethane exchange and twin-screw extrusion is described. The method may comprise introducing the polyurethane composition into a compounding device, heating the polyurethane composition to an effective bond-exchange temperature, and compounding the polyurethane composition for an effective bond-exchange time where the polyurethane composition comprises two or more network polymers and an effective amount of a polyurethane exchange catalyst permeated within the polyurethan composition.
B29C 48/00 - Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired formApparatus therefor
B29K 75/00 - Use of polyureas or polyurethanes as moulding material
C08J 11/18 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation by treatment with organic material
A method of making colloidal kagome superlattices can include functionalizing a plurality of metal nanoparticles with a plurality of oligonucleotides to produce programmable atom equivalents; and cooling the programmable atom equivalents to induce crystallization of the programmable atom equivalents. The cooling process can include cooling the PAEs from a first temperature to a second temperature at a first cooling rate, cooling the PAEs from the second temperature to a third temperature at a second cooling rate, and cooling the PAEs from the third temperature to a fourth temperature at a third cooling rate. The kagome superlattices can have a rhombohedral unit cell formed by alternating chiral layers of PAEs organized in 2-dimensional distorted kagome layers. The colloidal superlattices can have anisotropic light emission, Purcell factors of at least 25 and birefringent properties.
The present disclosure provides methods and compositions for targeting engineered lipid bilayer particles, such as secreted extracellular vesicles, and cargos included therein to recipient cells by displaying one or more signal regulatory protein alpha (SIRPa) on surfaces of the lipid bilayer particles.
A61K 9/1271 - Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
80.
ANNULOPLASTY RING FOR RECEIVING A REPLACEMENT VALVE
An annuloplasty ring includes an elastic elongated core having first regions and second regions, wherein the first regions are more stretchable than the second regions and are adapted for positioning at the commissures of a target native heart valve. The first regions and the second regions may enable the annuloplasty ring to both re-establish coaptation of the leaflets of a diseased native heart valve and establish a seal around a prosthetic replacement heart to prevent paravalvular leakage after a "Valve In Ring Procedure".
An annuloplasty ring includes an elastic elongated core having first regions and second regions, wherein the first regions are more stretchable than the second regions and are adapted for positioning at the commissures of a target native heart valve. The first regions and the second regions may enable the annuloplasty ring to both re-establish coaptation of the leaflets of a diseased native heart valve and establish a seal around a prosthetic replacement heart to prevent paravalvular leakage after a “Valve In Ring Procedure”.
A microplastic capture system includes a base and a plurality of hair-like protrusions mounted to and extending from the base. An oil is applied to the plurality of hair-like protrusions. The oil and hair-like protrusions are positioned to capture microplastic particles due to interfacial forces that oppose a force generated by momentum of the microplastic particles.
B01J 20/28 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof characterised by their form or physical properties
Ann and Robert H. Lurie Children's Hospital of Chicago (USA)
Inventor
Sharma, Arun
Fuller, Natalie J.
Bury, Matthew
Abstract
Disclosed are methods for regenerating bladder tissue. More specifically, disclosed are methods of regenerating bladder tissue by administering aryl hydrocarbon receptor effectors to a subject in need thereof.
Electrically conductive, metal-organic framework (MOF) materials, methods of making the materials, and chemical sensors incorporating the materials are provided. The electrically conductive MOF materials are formed from mesoporous MOF crystals having continuous strands of electrically conductive inorganic oxides within their porous structures. The inorganic strands are formed by the condensed-phase grafting of molecular metal species onto MOF nodes.
C07F 7/00 - Compounds containing elements of Groups 4 or 14 of the Periodic Table
B01J 20/28 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof characterised by their form or physical properties
C01B 37/00 - Compounds having molecular sieve properties but not having base-exchange properties
G01N 27/04 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance by investigating resistance
G01N 33/00 - Investigating or analysing materials by specific methods not covered by groups
Disclosed herein are a novel peptide and treatment for neurodevel opmental and psychiatric disorders. More specifically, disclosed herein is a composition and treatment based on administering to a subject an ectodomain that showed reduced levels in subjects with the disorder to treat negative and cognitive symptoms of said disorder.
ANN AND ROBERT H. LURIE CHILDREN'S HOSPITAL OF CHICAGO (USA)
Inventor
Rogers, John A.
Sharma, Arun K.
Madhvapathy, Surabhi Rao
Bury, Matthew I.
Abstract
The invention relates to device and method for monitoring of chronic intestinal inflammation of a subject. The device comprises a plurality of electronic components comprising at least one temperature sensor for measuring temperature of a target of interest of the subject in real-time, and a system on a chip having a microcontroller coupled to the at least one temperature sensor for transmitting data comprising the temperature wirelessly; and an elastomeric encapsulation layer at least partially surrounding the plurality of electronic components. The device is operably attached to the target of interest of the subject.
Provided herein are compositions comprising a copolymer comprising at least one sulfonatoalkoxy EDOT monomer (e.g. EDOT-S) or at least one cationic EDOT monomer and at least one heterocyclic monomer (e.g. an EDOT-OH monomer) and one or more bioactive peptide amphiphiles (PAs). The compositions provided herein find use in cell culture methods and in methods of promoting neural growth and maturation.
Provided herein are methods and systems for detecting one or more human papillomaviruses (HPV) in a biological sample. The methods can include detecting binding of an antibody or antibody fragment to DNA-RNA hybrids.
A method of simultaneously testing catalytic activity and/or selectivity of a plurality of catalyst includes coating a substrate having the plurality of catalyst with a polymer thin film having one or more reactive probes, subjecting the coated substrate to catalysis conditions corresponding to the target catalytic activity and/or selectivity, and imaging the coated substrate for the optical signal. Each reactive probe has a signaling component that generates an optical signal upon reaction of the probes with a product of the target catalytic activity and/or selectivity, thereby allowing sensing and signaling of the product of the target catalytic activity and/or selectivity. The presence of an optical signal in one or more regions of the coated substrate is indicative of catalysts of the plurality of catalyst in the one or more regions being active for the target catalytic activity and/or selectivity.
G01N 31/10 - Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroupsApparatus specially adapted for such methods using catalysis
90.
MIXED HALIDE PEROVSKITE, MEGALIBRARIES, HETEROSTRUCTURES AND SOLID SOLUTIONS AND METHODS OF FORMING THE SAME
A method of forming a combinatorial mixed halide perovskite library can include depositing an array of halide perovskite particles on a substrate. The method further includes exposing the array of halide perovskites to a laser to from defects in each of or a selected portion of the halide perovskite particles. The exposure conditions are modified across the array to generate a variation of defect concentration in the halide perovskite particles in the array. The defect containing halide perovskites are then exposed to an ion exchange solution and either anion exchanged or cation exchanged to thereby form a mixed halide perovskite particle.
ANN AND ROBERT H. LURIE CHILDREN’S HOSPITAL OF CHICAGO (USA)
THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (Canada)
SIBEL HEALTH INC. (USA)
Inventor
Rogers, John A.
Banks, Anthony R.
Yoo, Jaeyoung
Bharat, Ankit
Weese-Mayer, Debra E.
Shalish, Wissam
Oh, Seyong
Lee, Jong Yoon
Abstract
This invention relates to broadband acousto-mechanical sensing (BAMS) systems and methods for monitoring physiological signals of a living subject, and applications of the same. Specifically, the system includes one or more wireless, skin-interfaced BAMS devices disposed on the living subject to form a body area network. The BAMS devices are time-synchronized and wirelessly communicate with each other, and each BAMS device includes an accelerometer, such as an inertial measurement unit (IMU), to capture acceleration data from the living subject and an acoustic mechanical device configured to capture body sounds from the living subject. A control device being time-synchronized and wirelessly communicate with the BAMS devices is used to manage and process the acceleration data and the body sounds from the one or more BAMS devices in order to generate information of body movements and body sounds of the living subject.
A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
Metal organic resins, composite materials composed of the metal organic resins, and anion exchange columns packed with the composite materials are provided. Also provided are methods of using the composite materials to remove metal anions from a sample, methods of using the metal organic resins as fluorescence sensors for detecting metal anions in a sample, and methods of making the metal organic resins and the composite materials. The metal organic resins are amine-functionalized metal organic frameworks and their associated counter anions. The composite materials are composed of metal organic resin particles coated with organic polymers, such as alginic acid polymers.
B01J 20/22 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising organic material
B01D 53/02 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by adsorption, e.g. preparative gas chromatography
The present disclosure provides a system and method for analyzing an aorta of a subject using medical images. A machine learning algorithm is applied to provide aorta analysis based on the medical images. The aorta analysis includes standardized measurements of the aorta, which are mapped to a common aorta model to create personalized (e.g., subject specific) aorta heatmaps and/or to derive an aorta risk score for the subject.
IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (USA)
Inventor
Delferro, Massimiliano
Ferrandon, Magali S.
Poeppelmeier, Kenneth R.
Sadow, Aaron D.
Scott, Susannah
Lapointe, Anne M.
Coates, Geoffrey
Abstract
A method of upcycling polymers to useful hydrocarbon materials. A catalyst with nanoparticles on a substrate selectively docks and cleaves longer hydrocarbon chains over shorter hydrocarbon chains. The catalyst includes metal nanoparticles in an order array on a substrate.
A limb movement detection and stimulation system includes an orthosis configured to receive a limb of a patient. The system also includes one or more recording electrodes mounted to the orthosis and one or more stimulation electrodes mounted to the orthosis. The one or more stimulation electrodes are configured to stimulate the limb in response to the detected intended limb movement. The system also includes a processor operatively coupled to the orthosis. The processor is configured to determine. based on data sensed by the one or more recording electrodes. that the patient intends a limb movement. The processor is also configured to determine a movement state corresponding to the limb movement. and to energize the one or more stimulation electrodes to facilitate the movement state.
A61F 5/01 - Orthopaedic devices, e.g. long-term immobilising or pressure directing devices for treating broken or deformed bones such as splints, casts or braces
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/395 - Details of stimulation, e.g. nerve stimulation to elicit EMG response
The present disclosure provides methods for generating electricity. In embodiments, a method for generating electricity comprises injecting a liquid fuel composition comprising a hydrocarbon and water into a reformer, the reformer under a pressure and at an elevated temperature to convert the liquid fuel composition to a reformate composition via a reforming reaction, the reformate composition comprising hydrogen and methane; and introducing the reformate composition into an anode inlet port of a solid oxide fuel cell in fluid communication with the reformer while introducing oxygen into a cathode inlet port of the solid oxide fuel cell under conditions to convert the reformate composition into an exhaust composition while generating electricity. Systems for carrying out the methods are also provided.
H01M 8/0612 - Combination of fuel cells with means for production of reactants or for treatment of residues with means for production of gaseous reactants from carbon-containing material
Provided herein are methods to predict primary graft dysfunction in a subject, comprising detecting and/or quantifying complement protein in allograft biopsy tissue up to 120 minutes post-reperfusion.
Esophageal function and motility testing are provided using a catheter device having a proximal balloon coupled to a panometry catheter. Using this proximal balloon, esophageal physiology can be manipulated to test the presence of descending inhibition to diagnose achalasia and spastic esophageal disorders, among other esophageal disorders or conditions.
